G1T 38

Drug Profile

G1T 38

Alternative Names: G1T 38

Latest Information Update: 15 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator G1 Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Breast cancer
  • Phase I Cancer

Most Recent Events

  • 08 Nov 2017 G1 Therapeutics submits an IND application to the US Food and Drug Administration to evaluate G1T 38 in combination with Tagrisso® for the treatment of Non-small cell lung cancer
  • 09 Aug 2017 G1 Therapeutics announces intention to submit IND for Non-small cell lung cancer in the fourth quarter of 2017
  • 04 Apr 2017 G1 Therapeutics completes a phase I trial in Cancer (In volunteers) in the Netherlands (PO) (NCT02821624)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top